Clinical trials: Obese Patients
Obesity, Morbid, Bariatric Surgery Candidate
Health-connected Devices and Physical Activity Recovery in Bariatric Surgery Patients
The goal of clinical trial is to evaluate the impact of use of health-connected devices and of an Internet-based Intensive follow-up on physical activity recovery during the 6-month period after bariatric surgery in obese…
- Trial name
- MYGOODTRIP (NCT02716480)
- Testing
- Mobility coaching, Diet coaching
- Where
- France
- Volunteers
- 90 people
- Sponsor
- My Goodlife SAS
Obesity
A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients
The purpose of this study is to determine if CP-945,598 is effective in the treatment of obesity in type 2 diabetic patients.
- Trial name
- NCT00391196
- Testing
- CP-945,598, CP-945,598 Treatment B
- Where
- 91 sites in United States, Argentina and 9 more
- Volunteers
- 975 people
- Sponsor
- Pfizer
Obesity
Vestibular Stimulation to Trigger Adipose Loss (VeSTAL) Clinical Trial
A randomized, double blind sham controlled clinical trial to evaluate the efficacy of vestibular nerve stimulation (VeNS), combined with a lifestyle modification program, compared to a sham control and a lifestyle modification…
- Trial name
- VeSTAL (NCT03640286)
- Testing
- VeSTAL
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 241 people, healthy volunteers welcome
- Sponsor
- Neurovalens Ltd.
Overweight or Obesity
A Proof of Concept Trial in Overweight and Obese Patients, Investigating Effect of EMP16-02 on Body Weight (Primary)
This study is a proof of concept study to demonstrate that EMP16-02, a fixed dose combination (FDC) of orlistat and acarbose in an oral multiple-unit modified release (MR) formulation leads to a clinically relevant decrease in…
- Trial name
- NCT04521751
- Testing
- EMP16-02 120 mg orlistat/40 mg acarbose, EMP16-02 150 mg orlistat/50 mg acarbose
- Where
- 2 sites in Sweden
- Volunteers
- 156 people
- Sponsor
- Empros Pharma AB
Type 2 Diabetes Mellitus
Insulin Glulisine in Type 2 Diabetes Mellitus
Primary objective: To compare the pharmacodynamics of insulin glulisine and insulin lispro injected subcutaneously before three 500 kcal standard meals during a 12 hour day, in obese subjects with type 2 diabetes.
- Trial name
- NCT00310297
- Testing
- Insulin Glulisine
- Sponsor
- Sanofi
Chronic Respiratory Failure With Hypercapnia, Chronic Obstructive Pulmonary Disease (COPD)
Study Evaluating Telemonitoring and Experimentation in Telemedicine for the Improvement of Healthcare Pathways (ETAPES Program) Compared to Standard of Care in Patients With Chronic Respiratory Failure Receiving Non-invasive Home Ventilation
The ETAPES Program, a French national Experimentation in Telemedicine for the Improvement of Healthcare Pathways, was launched in 2018 for 4 years.
- Conditions
- Chronic Respiratory Failure With Hypercapnia, Chronic Obstructive Pulmonary Disease (COPD), Obesity Hypoventilation Syndrome (OHS)
- Trial name
- e-VENT (NCT04615078)
- Testing
- ETAPES Program
- Where
- 11 sites in France
- Volunteers
- 56 people
- Sponsor
- Air Liquide Santé International
Acute Respiratory Failure, Coma
EASiVENT Study Comparing INTELLiVENT-ASV vs Non Automated Ventilation in Adult ICU Patients
The purpose of the study is to assess the safety and efficacy of INTELLiVENT-ASV (Adaptive Support Ventilation) in adult ICU patients comparing to non automated ventilation.
- Conditions
- Acute Respiratory Failure, Coma, Acute Respiratory Distress Syndrome (ARDS), Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT04400643
- Testing
- INTELLiVENT-ASV, Non-automated ventilation
- Where
- Portugal
- Volunteers
- 62 people
- Sponsor
- Hamilton Medical AG
Hypothalamic Obesity
A Study of Octreotide Depot vs Saline Control in Pediatric Hypothalamic Obesity Patients
The extension protocol is designed to allow those patients randomized to placebo in the core portion of the protocol to receive a 6 month treatment of open label octreotide and allow those patients randomized to octreotide who…
- Trial name
- NCT00171613
- Testing
- Octreotide
- Volunteers
- 32 people
- Sponsor
- Novartis
Binge-Eating Disorder
Reduction of the Speed of Eating as an Intervention in Obesity
Patients diagnosed with Binge Eating Disorder (BED) overeat food but, as opposed to patients with bulimia nervosa, they do not compensate for their increased food intake and therefore their body weight increases.
- Trial name
- NCT02381327
- Testing
- Mandometer
- Where
- Sweden
- Volunteers
- 386 people, healthy volunteers welcome
- Sponsor
- Mando Group AB
Obesity
INSPIRE Turkey :A Research Study Looking at the Clinical Parameters Associated With Use and Discontinuation of Saxenda® in Local Clinical Practice in Turkey by Analysing Past Patient Medical Records
The study is investigating the use of Saxenda (liragltuide 3.0 milligrams (mg) once daily) for weight management. The primary objective is to investigate the change in body weight after initiation and use of Saxenda ® according…
- Trial name
- INSPIRE Turkey (NCT05438186)
- Testing
- Liraglutide
- Where
- Turkey (Türkiye)
- Sponsor
- Novo Nordisk A/S
COPD (Chronic Obstructive Pulmonary Disease), Obesity Hypoventilation Syndrome (OHS)
The Effect of Mask Design on Ventilation Parameters in COPD and OHS Patients on Long-term Home Non-invasive Ventilation. An Experimental Study.
Chronic obstructive pulmonary disease (COPD) and obesity hypoventilation syndrome (OHS) are respiratory conditions that disrupt normal breathing.
- Trial name
- NCT06972589
- Testing
- Investigational Mask, Conventional mask
- Where
- New Zealand
- Volunteers
- 20 people
- Sponsor
- Fisher and Paykel Healthcare
Obesity
StomaphyX Versus Sham for Revisional Surgery in Post-Roux-en-Y Patients to Reduce Regained Weight
The Roux-en-Y gastric bypass (RNYGB) is a weight loss surgery that involves the creation of a small gastric pouch and rearrangement of the small intestine.
- Trial name
- NCT00939055
- Testing
- StomaphyX
- Where
- 2 sites in United States
- Volunteers
- 112 people
- Sponsor
- EndoGastric Solutions
Overweight, Obesity
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity
The researchers are doing the study to see if semaglutide may reduce the risk of having cardiovascular events in patients with overweight or obesity and with prior cardiovascular disease.
- Trial name
- SELECT (NCT03574597)
- Testing
- Semaglutide
- Where
- 833 sites in United States, Algeria and 40 more
- Volunteers
- 17,604 people
- Sponsor
- Novo Nordisk A/S
Obesity
Lorcaserin and Behavioral Modification for Overweight and Obesity Management in Chinese Obese Patients
The purpose of this study is to assess the safety and weight loss effect of lorcaserin at the end of the first year of treatment (Week 48) in overweight and Chinese adult obese patients compared to placebo.
- Trial name
- NCT03720574
- Testing
- Lorcaserin 10 mg BID
- Where
- 9 sites in China
- Volunteers
- 100 people
- Sponsor
- Kanion & Huawe Medicine Co.,Ltd
Prader-Willi Syndrome
An Open-Label Study of DCCR Tablet in Patients With PWS
The primary objective of this study is to monitor the long-term safety of DCCR in PWS patients.
- Trial name
- NCT04086810
- Testing
- DCCR
- Sponsor
- Soleno Therapeutics, Inc.
Overweight (BMI > 25), Obesity & Overweight
Global Overweight and oBesE (GLOBE) Patient Registry, Development and Implementation of Disease-specific: Severity, Quality of Life and Cost Instruments.
We are conducting this study to develop a disease-specific instrument, a quality of life instrument and a comprehensive list of costs associated with overweight and obesity.
- Trial name
- GLOBE (NCT07229027)
- Where
- United Kingdom
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Medialis Ltd.
Obesity
Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity
This study is a multicenter, randomized, partially double-blind (double-blind in both the IBI362 group and the placebo group, with the tirbopeptide group open), placebo and active drug controlled design study
- Trial name
- NCT07000955
- Testing
- Tirzepatide, IBI362
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Obesity, Overweight
A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA) being developed for chronic weight…
- Conditions
- Obesity, Overweight, Type 2 Diabetes Mellitus (T2DM)
- Trial name
- NCT07670416
- Testing
- Enicepatide
- Where
- 21 sites in China
- Volunteers
- 300 people
- Sponsor
- Hoffmann-La Roche
Prader-Willi Syndrome
A Phase 3 Extension Study of RAD011 (Cannabidiol Oral Solution) in Patients With Prader-Willi Syndrome
This is a Phase 3 open-label extension (OLE) study in patients diagnosed with Prader-Willi Syndrome (PWS) who completed the Maintenance Period of the randomized, placebo-controlled Phase 2/3 study SCOUT-015.
- Trial name
- NCT05387798
- Testing
- RAD011
- Sponsor
- Radius Pharmaceuticals, Inc.
Adiposity, Morbid
Endoscopic Gastric Mucosal Ablation (GMA) of Class III Obesity
This study is intended to investigate safety and feasibility of a new weight loss technique called Gastric Mucosal Ablation (GMA) that does not require surgery, but can be achieved using an endoscopic procedure.
- Conditions
- Adiposity, Morbid, Obesity
- Trial name
- NCT05574777
- Testing
- Hybrid Argonplasma coagulation (HAPC)
- Where
- Brazil
- Volunteers
- 13 people
- Sponsor
- Erbe Elektromedizin GmbH